Teva receives first u.s. approval for generic pulmicort respules; commences commercial launch Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca's Pulmicort (Budesonide) Respules, 0.25 mg/2 mL and 0.5 mg/2 mL indicated for twice daily treatment of Asthma. Shipment of these products has commenced. [more...]
